Personalised Genetic Intervention for Duchenne Muscular Dystrophy: Antisense Oligomers and Exon Skipping

E-ISSN： 1874-4702|2|1|110-121

ISSN： 1874-4672

Source： Current Molecular Pharmacology, Vol.2, Iss.1, 2009-01, pp. : 110-121

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges

Current Gene Therapy, Vol. 12, Iss. 3, 2012-06 ,pp. : 152-160

Bentham Science Publishers

Access to resources Recommend Favorite

Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD)

Current Gene Therapy, Vol. 15, Iss. 4, 2015-01 ,pp. : 395-415

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for Duchenne muscular dystrophy

By Malik Vinod Rodino-Klapac Louise R. Mendell Jerry R

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 2, 2012-06 ,pp. : 261-277

Informa Healthcare

Access to resources Recommend Favorite

Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy

By ’t Hoen Peter AC van der Wees Caroline GC Aartsma-Rus Annemieke Turk Rolf Goyenvalle Aurélie Danos Olivier Garcia Luis van Ommen Gert-Jan B den Dunnen Johan T van Deutekom Judith CT

Pharmacogenomics, Vol. 7, Iss. 3, 2006-04 ,pp. : 281-297

Future Medicine

Access to resources Recommend Favorite

Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy

By Judge Daniel P. Kass David A. Thompson W. Reid Wagner Kathryn R.

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 5, 2011-10 ,pp. : 287-294

Adis International

Access to resources Recommend Favorite